Hummingbird Diagnostics develops advanced molecular blood tests that analyze both tumor and immune system small RNA biomarkers. Their mirCator platform enhances diagnostic accuracy for early disease detection, response prediction, and treatment monitoring across various medical fields.
Funding
Funding not disclosed
Founders
Product
Problem
Current diagnostic methods for cancer and other diseases often rely on single biomarker analyses, which can limit sensitivity and specificity. This can lead to delayed detection, inaccurate prediction of treatment response, and suboptimal disease management.
Solution
Hummingbird Diagnostics develops advanced molecular blood tests that integrate both tumor-derived and host immune system biomarkers. Their proprietary mirCator platform analyzes small RNA signatures from whole blood, providing a comprehensive view of disease state and immune response. This dual interrogation approach enhances diagnostic accuracy for early detection, response prediction, and treatment monitoring. The platform is designed to be disease-agnostic, enabling applications across various medical fields, including oncology and neurodegenerative diseases.
Target Audience
The primary customers are pharmaceutical companies, clinical research organizations, and diagnostic laboratories seeking advanced biomarker discovery and diagnostic solutions for precision medicine.
Features
- Integrated analysis of disease and host immune response small RNA biomarkers from whole blood.
- AI-powered mirCator platform for comprehensive small RNA analysis and mapping.
- End-to-end operational process coverage, from sample collection to data analysis.
- Streamlined sample collection with immediate stabilization and -20°C storage.
- Automated, high-yield analyte extraction optimized for small RNAs.
- Ultra-deep quantification of small RNA biomarkers using NGS and proprietary blocking technology.
- Digital PCR validation for single nucleotide resolution.
- Proprietary software suite including Classifynder for biomarker discovery and TransfoRNA for AI-driven annotation.
- miR-Blood atlas and database providing high-quality small RNA expression data for peripheral blood components.
- Disease-agnostic platform applicable to oncology, neurodegenerative diseases, and other conditions.